Lipitor
US drug spend soars to all-time high in 2014
April 14, 2015Manufacturing and Production, Sales and Marketing Lipitor, Obama, UK Health and Social Care Information Centre, US, drug spend, prescribing
The number of prescriptions dispensed in the US rose by 13% in 2014 a new report has shown. The increase …
Pfizer posts fourth-quarter revenue decline
January 28, 2015Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate
Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …
Pfizer revenue drops, but new cancer drugs shine
July 29, 2014Research and Development, Sales and Marketing Cancer, Inlyta. axitinib, Lipitor, Lyrica, Pfizer, Q2, Sutent, viagra
Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …
Copycat Lipitor helps toward £1.3bn NHS savings
July 29, 2014Research and Development, Sales and Marketing ABPI, Lipitor, NHS, Teva, prescribing PPRS, vba
In 2013 generic usage increased to more than three-quarters of all NHS prescriptions according to new data released by the …
Pfizer faces Australia action
February 14, 2014Medical Communications, Sales and Marketing Australia, Lipitor, Pfizer, accc
Pfizer has a legal battle on its hands in Australia, where the country’s consumer watchdog has begun proceedings in the …
Profits drop for Pfizer
January 29, 2014Sales and Marketing Enbrel, Lipitor, Pfizer, Spiriva, Zoetis, q4
Pfizer’s turnover fell to $54.6 billion in 2013, a 6% drop year-on-year from $54.7 billion in 2012, but the group …
Cancer drugs lift Pfizer in third quarter
October 30, 2013Sales and Marketing Lipitor, Lyrica, Pfizer, Q3, Xalkori
Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …
Lipitor competition holds Pfizer back
July 31, 2013Sales and Marketing Lipitor, Pfizer, Prevnar, Q2
Pfizer’s revenues in the second quarter of 2013 fell 7% year-on-year, in part due to the loss of patent in …
Pfizer sales shrink 9 per cent
April 30, 2013Sales and Marketing Ian Read, Lipitor, Pfizer
Pfizer endured another painful cut to its revenues in the first quarter of 2013, with sales down $1.4 billion, or …
Glass particles force recall of Ranbaxy Lipitor
November 27, 2012Manufacturing and Production, Sales and Marketing Daiichi Sankyo, Lipitor, Pfizer, Ranbaxy, recall
Ranbaxy Pharmaceuticals is recalling around 40 batches of its generic atorvastatin tablets after discovering that some of the product may …
Pfizer stumbles in third quarter
November 2, 2012Research and Development, Sales and Marketing Ian Read, Lipitor, Pfizer, Prevnar, Q3
Pfizer has experienced a worse than expected third quarter, due to disappointing sales of paediatric vaccine Prevnar and a surprise …
Lipitor loss continues to hit Pfizer sales
July 31, 2012Sales and Marketing Enbrel, Lipitor, Pfizer, Prevnar, Q2
Pfizer has posted a loss in revenue for the second quarter as the firm continues to feel the impact of …
Lipitor fallout prompts Pfizer to cut Irish workforce
June 7, 2012Manufacturing and Production Amgen, Ireland, Lipitor, Pfizer, cuts, patent loss
Falling demand for blockbuster cholesterol drug Lipitor has prompted Pfizer to cut staff levels at two manufacturing facilities in Ireland. …
Plavix loses US patent protection
May 18, 2012Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi
Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US. The drug, which made $6.6 …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
